RESUMO
The Globally Harmonised System of Classification (GHS) is a framework within which the intrinsic hazards of substances may be determined and communicated. It is not a legislative instrument per se, but is enacted into national legislation with the appropriate legislative instruments. GHS covers many aspects of effects upon health and the environment, including adverse effects upon sexual function and fertility or on development. Classification for these effects is based upon observations in humans or from properly designed experiments in animals, although only the latter is covered herein. The decision to classify a substance based upon experimental data, and the category of classification ascribed, is determined by the level of evidence that is available for an adverse effect on sexual function and fertility or on development that does not arise as a secondary non-specific consequence of other toxic effect. This document offers guidance on the determination of level of concern as a measure of adversity, and the level of evidence to ascribe classification based on data from tests in laboratory animals.
Assuntos
Substâncias Perigosas/classificação , Substâncias Perigosas/toxicidade , Reprodução/efeitos dos fármacos , Animais , Butadienos/classificação , Butadienos/toxicidade , Etanolaminas/classificação , Etanolaminas/toxicidade , Feminino , Guias como Assunto , Internacionalidade , Masculino , Nitrobenzenos/classificação , Nitrobenzenos/toxicidade , Ácidos Ftálicos/classificação , Ácidos Ftálicos/toxicidade , Rotulagem de Produtos , Testes de ToxicidadeRESUMO
Nebivolol (Nomexor) is a third generation, vasodilating beta-blocker with a high beta(1)-adrenoceptor selectivity. Nebivolol acts as an agonist at the beta(3) adrenoceptor as well as the estrogen receptor thereby releasing nitric oxide in blood vessels via eNOS. Pleiotropic effects of nebivolol furthermore include a positive influence on cholesterol and triglycerides and a decrease in thrombocyte activity. Nebivolol is recommended in the guidelines of the European cardiac society (ESC) for patients with metabolic syndrome. Nebivolol's main properties in combination with its broad range of beneficial pleiotropic effects allow it to be clearly distinguished from other second and third generation beta-blockers.
Assuntos
Agonistas Adrenérgicos beta/uso terapêutico , Benzopiranos/uso terapêutico , Etanolaminas/uso terapêutico , Síndrome Metabólica/tratamento farmacológico , Vasodilatadores/uso terapêutico , Agonistas Adrenérgicos beta/efeitos adversos , Agonistas Adrenérgicos beta/classificação , Idoso , Idoso de 80 Anos ou mais , Animais , Apoptose/efeitos dos fármacos , Benzopiranos/efeitos adversos , Benzopiranos/classificação , Pressão Sanguínea/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Fatores Relaxantes Dependentes do Endotélio/sangue , Etanolaminas/efeitos adversos , Etanolaminas/classificação , Humanos , Hipertensão/sangue , Hipertensão/tratamento farmacológico , Lipídeos/sangue , Síndrome Metabólica/sangue , Camundongos , Nebivolol , Óxido Nítrico/sangue , Agregação Plaquetária/efeitos dos fármacos , Ensaios Clínicos Controlados Aleatórios como Assunto , Pesquisa , Resistência Vascular/efeitos dos fármacos , Vasodilatadores/efeitos adversos , Vasodilatadores/classificaçãoRESUMO
Several brain receptor systems can modulate food intake. Thus, in a new strategy against obesity, the patient takes submaximal doses of two drugs that act by differing mechanisms.
